89bio Inc (ETNB)
8.75
-0.16
(-1.85%)
USD |
NASDAQ |
Nov 14, 16:00
8.50
-0.25
(-2.86%)
After-Hours: 20:00
89bio Cash from Operations (Quarterly): -145.36M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -145.36M |
| June 30, 2024 | -61.16M |
| March 31, 2024 | -39.72M |
| December 31, 2023 | -34.29M |
| September 30, 2023 | -30.36M |
| June 30, 2023 | -34.45M |
| March 31, 2023 | -30.08M |
| December 31, 2022 | -27.10M |
| September 30, 2022 | -14.82M |
| June 30, 2022 | -14.84M |
| March 31, 2022 | -24.34M |
| December 31, 2021 | -28.24M |
| Date | Value |
|---|---|
| September 30, 2021 | -13.45M |
| June 30, 2021 | -20.11M |
| March 31, 2021 | -14.98M |
| December 31, 2020 | -14.03M |
| September 30, 2020 | -12.94M |
| June 30, 2020 | -11.52M |
| March 31, 2020 | -7.752M |
| December 31, 2019 | -11.13M |
| September 30, 2019 | -6.197M |
| June 30, 2019 | -3.964M |
| March 31, 2019 | -4.167M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-145.36M
Minimum
Sep 2024
-7.752M
Maximum
Mar 2020
-29.53M
Average
-22.23M
Median
Cash from Operations (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -66.98M |
| Eli Lilly and Co | 3.712B |
| Viking Therapeutics Inc | -21.96M |
| Akero Therapeutics Inc | -70.42M |
| NovaBay Pharmaceuticals Inc | -2.061M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -8.639M |
| Cash from Financing (Quarterly) | 33.19M |
| Free Cash Flow | -280.54M |
| Free Cash Flow Per Share (Quarterly) | -1.358 |
| Free Cash Flow Yield | -33.44% |